^
Association details:
| Biomarker: | KRAS mutation + STK11 mutation + KEAP1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS- mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Published date:
02/21/2022
Excerpt:
IMpower150 was an international, open-label, randomized, phase III trial of ACP or ABCP vs BCP in 1202 patients with NSCLC enrolled....In patients with mKRAS and co-occurring mSTK11 and/or mKEAP1 tumors (figure 4A), a longer OS was observed in the ABCP arm (median, 11.1 months; HR 0.60; 95% CI 0.34 to 1.03) than in the ACP arm (median, 7.9 months; HR 0.87; 95% CI 0.52 to 1.45) vs the BCP arm (median 8.7 months). A similar effect was also observed with PFS: ABCP (median 6.0 months; HR 0.49; 95% CI 0.28 to 0.84) and ACP (median 3.2 months; HR 0.88; 95% CI 0.54 to 1.46) vs BCP (median 3.4 months) (figure 4B).
Secondary therapy:
Chemotherapy
DOI:
10.1136/jitc-2021-003027
Trial ID:
